MorphoSys Accelerates Antibody R&D with Genedata Biologics

MorphoSys, a late-stage biopharmaceutical company, was facing challenges due to its rapid growth. The increase in molecule and sample throughput led to a significant amount of R&D data, which was difficult to capture, process, and interpret. The scale and throughput of their operations necessitated the use of an enterprise workflow platform to manage and streamline the growing number of their discovery programs. The goal of the new system was to make MorphoSys’ sophisticated R&D processes more efficient and to facilitate handovers between various R&D teams and functions, including screening, molecular biology, engineering, expression, purification, and analytics. The new system also needed to be able to handle the increasing amount of data and samples produced by external partners, such as CROs, which had to be integrated into MorphoSys’ R&D process.

MorphoSys is a late-stage biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its proprietary technology platforms and leadership in the field of therapeutic antibodies, MorphoSys, together with its partners, has participated in the development of more than 100 therapeutic product candidates currently in R&D. The company has one of the broadest pipelines in the biotechnology industry, including unique approaches for patients with conditions such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. The MorphoSys pipeline is based on a combination of strong business partnerships and proprietary development activities. MorphoSys has partnered with major biopharmaceutical companies including Astellas, Bayer, Merck & Co., Boehringer Ingelheim, Novartis, Janssen, Pfizer, Daiichi Sankyo, F. Hoffmann-La Roche, and Shionogi. Using MorphoSys’ proprietary synthetic antibody libraries and their phage display screening technologies HuCAL, Ylanthia, and Slonomics, MorphoSys enables faster, more flexible and, ultimately, better-quality access to drug candidates.